Cancer Search logoCancer Search
  1. Home
  2. Cancer Clinical Trials
  3. 33 PD-L1 High Expression (TPS >= 50%) Cancer Clinical Trials

PD-L1 High Expression (TPS >= 50%)
{name}
{subtitle}
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
city
121 sites for NCT04660344
biomarker
PD-L1 Expression (CPS >= 1), +5 more biomarkers
condition
Infiltrating Bladder Urothelial Carcinoma
drug
atezolizumab
drug type
immunotherapy
Recruiting
Phase 3
link NCT04660344
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
city
116 sites for NCT04740918
biomarker
ERBB2 Amplification, +7 more biomarkers
condition
Breast Carcinoma
drug
ado-trastuzumab emtansine, +1 more drug
drug type
immunotherapy, +1 more type
Recruiting
Phase 3
link NCT04740918
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
city
207 sites for NCT04513925
biomarker
PD-L1 Expression (CPS >= 1), +5 more biomarkers
condition
Non-Small Cell Lung Carcinoma
drug
atezolizumab, +1 more drug
drug type
immunotherapy
Recruiting
Phase 3
link NCT04513925
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
city
161 sites for NCT04746924
biomarker
PD-L1 High Expression (TPS >= 50%)
condition
Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition
drug
ociperlimab, +1 more drug
drug type
immunotherapy
Recruiting
Phase 3
link NCT04746924
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
city
51 sites for NCT04665843
biomarker
PD-L1 Expression (CPS >= 1), +5 more biomarkers
condition
Head and Neck Squamous Cell Carcinoma
drug
atezolizumab, +1 more drug
drug type
immunotherapy
Recruiting
Phase 2
link NCT04665843
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
city
67 sites for NCT04262856
biomarker
PD-L1 Expression (CPS >= 1), +5 more biomarkers
condition
Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition
drug
domvanalimab, +2 more drugs
drug type
immunotherapy
Recruiting
Phase 2
link NCT04262856
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
city
45 sites for NCT04463771
biomarker
Deficient DNA Mismatch Repair (dMMR), +23 more biomarkers
condition
Endometrial Carcinoma, +2 more conditions
drug
epacadostat, +2 more drugs
drug type
immunotherapy, +1 more type
Recruiting
Phase 2
link NCT04463771
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
city
30 sites for NCT03337698
biomarker
PD-L1 High Expression (TPS >= 50%)
condition
Non-Small Cell Lung Carcinoma
drug
atezolizumab, +14 more drugs
drug type
chemotherapy, +4 more types
Recruiting
Phase 1/2
link NCT03337698
CRAFT: The NCT-PMO-1602 Phase II Trial
city
4 sites for NCT04551521
biomarker
AKT1 Amplification, +78 more biomarkers
condition
Malignant Solid Tumor
drug
alectinib, +6 more drugs
drug type
immunotherapy, +1 more type
Recruiting
Phase 2
link NCT04551521
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
city
7 sites for NCT04931654
biomarker
PD-L1 High Expression (TPS >= 1%), +2 more biomarkers
condition
Non-Small Cell Lung Carcinoma, +1 more condition
drug
AZD7789
drug type
immunotherapy
Recruiting
Phase 1/2
link NCT04931654
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
city
1 site for NCT04849364
biomarker
AKT1 Amplification, +141 more biomarkers
condition
Invasive Breast Carcinoma
drug
atezolizumab, +3 more drugs
drug type
chemotherapy, +2 more types
Recruiting
Phase 2
link NCT04849364
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
city
23 sites for NCT04291105
biomarker
PD-L1 High Expression (TPS >= 50%)
condition
Cutaneous Melanoma, +3 more conditions
drug
cemiplimab, +2 more drugs
drug type
immunotherapy
Recruiting
Phase 2
link NCT04291105
33 Items
Page 1 of 3
Open Page 2  →
Main Menu
Clinical Trials
Therapies
Biomarkers
Cancer Types
Drugs
About
Cancer Search
Terms
Site Map
Credits
FAQ
Powered By
GenomOncology, LLC Logo
Copyright © 2022 GenomOncology, LLC